Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma

免疫疗法反应诱导肝细胞癌中出现不同的三级淋巴结构形态

阅读:2
作者:Daniel H Shu ,Won Jin Ho ,Luciane T Kagohara ,Alexander Girgis ,Sarah M Shin ,Ludmila Danilova ,Jae W Lee ,Dimitrios N Sidiropoulos ,Sarah Mitchell ,Kabeer Munjal ,Kathryn Howe ,Kayla J Bendinelli ,Emma Kartalia ,Hanfei Qi ,Guanglan Mo ,Janelle Montagne ,James M Leatherman ,Tamara Y Lopez-Vidal ,Qingfeng Zhu ,Amanda L Huff ,Xuan Yuan ,Alexei Hernandez ,Erin M Coyne ,Neeha Zaidi ,Daniel J Zabransky ,Logan L Engle ,Aleksandra Ogurtsova ,Marina Baretti ,Daniel Laheru ,Jennifer N Durham ,Hao Wang ,Joel C Sunshine ,Robert J Johnston ,Julie Stein Deutsch ,Janis M Taube ,Robert A Anders ,Elizabeth M Jaffee ,Elana J Fertig ,Mark Yarchoan

Abstract

Tertiary lymphoid structures (TLS) are associated with improved response in solid tumors treated with immune checkpoint blockade, but understanding of the prognostic and predictive value of TLS and the circumstances of their resolution is incomplete. Here we show that in hepatocellular carcinoma treated with neoadjuvant immunotherapy, high intratumoral TLS density at the time of surgery is associated with pathologic response and improved relapse-free survival. In areas of tumor regression, we identify a noncanonical involuted morphology of TLS marked by dispersion of the B cell follicle, persistence of a T cell zone enriched for T cell-mature dendritic cell interactions and increased expression of T cell memory markers. Collectively, these data suggest that TLS can serve as both a prognostic and predictive marker of response to immunotherapy in hepatocellular carcinoma and that late-stage TLS may support T cell memory formation after elimination of a viable tumor.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。